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Abstract
CNS relapse is reported in 2–5% of diffuse large B- cell lymphoma (DLBCL) 
patients, dramatically decreasing overall survival (OS). Very few studies address 
incidence and risk factors of CNS relapse in very elderly patients, a challenging 
population to treat given their commonly associated comorbidities. A retrospec-
tive analysis was performed of 270 DLBCL patients >80 years treated between 
2004 and 2013 in two multicentre phase II LYSA trials (LNH03- 7B, LNH09- 7B) 
evaluating the addition of rituximab or ofatumumab to mini- CHOP as front- 
line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated 
according to cumulative incidence, patient characteristics, risk factors, and sur-
vival. Median age was 83 years (range: 79–95). After a median follow- up of 
28.7 months, eight patients had CNS relapse (3.0%). Median time between 
inclusion and CNS relapse was 19.2 months (range: 3.2–32.6). Patients survived 
a median of 1.5 months after CNS relapse (range: 0.4–4.1). Median OS from 
relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 
0.4–3.5) compared to patients with non- CNS relapse (6.6 months; 95% CI: 
4.6–11.9). No baseline characteristics were associated with CNS relapse. The 
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Introduction
Diffuse large B- cell lymphoma (DLBCL) is the most 
common lymphoid malignancy worldwide. The prevalence 
of DLBCL patients aged 80–84 years is reported to be 
2.5- fold higher than that of patients aged 60–64 years 
[1]. Treating very elderly patients is particularly chal-
lenging given the likelihood of comorbidities and concerns 
over risks of toxicity. Poorer survival outcomes are seen 
in this population despite a clinical presentation and 
prognostic parameters similar to those of younger patients, 
with retrospective and prospective studies placing median 
overall survival (OS) in this older population in the 
range of 2.0–2.5 years [2–4]. Disease progression is the 
main cause of death in approximately half of these 
patients.
Central nervous system (CNS) relapse is one of the 
most devastating and rapidly fatal complication in DLBCL, 
which occurs in around 2–5% of DLBCL patients [5–10], 
dramatically shortening OS, often to less than 6 months 
after CNS relapse. Although contentious, several risk fac-
tors have been reported to be associated with higher relapse 
rates, including advanced disease stage (Ann Arbor stage 
III or IV), elevated lactate dehydrogenase (LDH) levels, 
Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) of 2 or more, involvement of more than two 
extranodal sites, age- adjusted international prognostic 
index (aaIPI) of 2 or more, involvement of the testis, 
breast, or the ovaries (considered organs with immune 
privilege), or involvement of the base of the skull [11–14]. 
The CNS international prognostic index (CNS- IPI) is a 
validated tool for classifying DLBCL patients into three 
risk groups for CNS relapse [15]. The model uses kidney 
and/or adrenal gland involvement as well as the IPI. 
Patients in the low- and intermediate- risk groups are 
associated with a risk <5% while the high- risk group is 
associated with a > 10% risk. CNS prophylaxis is gener-
ally proposed to high- risk subgroups. Although there is 
currently no consensus for the optimal CNS prophylactic 
strategy, intrathecal or high- dose intravenous methotrexate 
is usually used [13, 14, 16, 17].
Most studies reporting incidence and risk factors of 
CNS relapse concern DLBCL patients under the age of 
80 years [18, 19], and little is known about CNS 
recurrence in the very elderly, aged over 80 years. CNS 
prophylaxis is rarely implemented in this population 
due to the burden of comorbidities with frequent anti-
platelet or anticoagulant treatment (renal failure, and 
hypoalbuminemia), as well as the potential toxicity of 
the prophylaxis. We retrospectively evaluated CNS 
relapse in very elderly DLBCL patients aged 80 years 
or older, treated in two prospective LYSA studies with 
miniCHOP therapy, associated with either rituximab 
or ofatumumab, another anti- CD20 monoclonal anti-
body. CNS relapse incidence, risk factors, and specific 
survival in this population were analyzed, with the aim 
of fine- tuning therapeutic management of this fragile 
population.
Patients and Methods
Clinical studies and patient population
Data were collected retrospectively from two multicentre, 
phase II, open- label, single arm LYSA trials conducted in 
France and Belgium, LNH03- 7B (NCT01087424) between 
2004 and 2007 and LNH09- 7B (NCT01195714) between 
2009 and 2013. Results of these studies are presented 
elsewhere [4, 20]. Main inclusion criteria for both studies 
were previously untreated CD20 +  DLBCL (diagnosis of 
aggressive lymphoma confirmed by an expert hemato-
pathologist panel), follicular lymphoma grade 3B, or de 
novo transformed follicular lymphoma, age over 80 years, 
Ann Arbor stage of I bulky, II, III or IV, aaIPI ≤ 3, no 
previous DLBCL treatment, ECOG PS ≤2 for LNH03- 7B 
or any PS for LNH09- 7B, and recent negative HIV, HBV, 
and HCV serology. Main exclusion criteria were a history 
of treated or nontreated indolent lymphoma, CNS or 
meningeal involvement, creatinine > 150 μmol/L, total 
bilirubin > 30 mmol/L, transaminases > 2.5 times the 
upper normal limit (unless disease- related), neutro-
phils < 1.5 G/L, or platelets < 100 G/L. All patients signed 
written informed consent. Studies were approved by an 
independent research ethics committee and were carried 
out in accordance with the International Conference on 
Harmonisation Good Clinical Practice Guidelines, the 
Declaration of Helsinki, and local regulatory requirements 
and laws.
proportion of patients with CNS disease did not differ significantly between 
patients with low- intermediate risk according to CNS- IPI and patients with high 
risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly 
treatment- naive patients is 1.8% at 2 years and is associated with poor survival. 
This population had a long median time to CNS relapse. Absence of prophylaxis 
did not strongly impact CNS relapse incidence.
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Treatment
Patients in the LNH03- 7B study received rituximab- 
miniCHOP (R- miniCHOP). In the LNH09- 7B study, 
ofatumumab was associated with miniCHOP 
(O- miniCHOP). MiniCHOP consisted of cyclophospha-
mide (400 mg/m²), doxorubicin (25 mg/m²), and vincristine 
(1 mg) on day 1 of each cycle and oral prednisone (40 mg/
m²) on days 1–5. For LNH03- 7B rituximab (375 mg/m²) 
was administered on day 1. LNH09- 7B included a pre- 
phase of oral prednisone and vincristine, then ofatumumab 
(1000 mg/m²) on day 1. Six 3- week cycles were planned. 
CNS prophylaxis was not recommended and no patients 
received prophylaxis for CNS relapse. At relapse, diagnosis 
of CNS disease was based on symptoms and radiological 
finding including a brain scan and/or MRI.
Data collection
Data from the initial clinical examination, laboratory tests, 
chest X- ray, abdominal sonography, computed tomography 
of thorax, and abdomen and a bone marrow biopsy were 
collected, along with follow- up data for disease progres-
sion and survival. Staging was based on thoracic and 
abdominal computerized scan. Tumor measurements were 
assessed by the treating physician or local radiologist, and 
bulky disease was defined as any mass with a maximum 
diameter of 10 cm or more. Cerebrospinal fluid examina-
tion, bone marrow biopsy, and 18Fluorodeoxyglucose PET 
was not mandatory for staging or for assessment of response.
Statistical analysis
Cumulative incidence of CNS relapse was calculated using 
the competing risk method, considering non- CNS relapse 
and death without relapse as competing risks. We con-
trolled for the effects of prognostic factors on outcome 
using the competing risk formulation of Cox model regres-
sion which investigates the effect of explanatory variables 
on different competing events, such as CNS relapse, non- 
CNS relapse, or death during course of a disease. 
Progression- free survival (PFS) was calculated from the 
date of diagnosis to the date of progression, relapse, or 
death from any cause. Overall survival (OS) was calculated 
from the date of diagnosis to the date of death from any 
cause. The impact of CNS relapse on PFS and OS analyses 
was performed in the global population and in a subset 
of patients with relapse. Survival functions were estimated 
by the Kaplan–Meier method and compared by the log- 
rank test. Comparisons between patients with and without 
CNS disease were performed by Fisher’s exact test for 
discrete variables and Wilcoxon Mann–Whitney test for 
continuous variables. Potential predictive covariates of CNS 
relapse analyzed were sex, Ann Arbor stage, ECOG PS, 
LDH level, number of extranodal sites, aaIPI, IPI, involve-
ment of specific extranodal sites (breast, gonads, kidney, 
adrenal, cavum, bone marrow), histological parameters 
(Hans score, MYC status, and cMYC value), and CNS- 
IPI. Analyses were performed with SAS 9.2 (SAS Institute, 
Cary, NC).
Results
Patient characteristics
Our study population concerns the 270 patients included 
in the two trials, consisting of 150 in the LNH03- 7B 
treated with R- miniCHOP and 120 in the LNH0- 97B 
treated with O- miniCHOP. Patient characteristics in the 
overall population are presented in Table 1. Median age 
was 83 years (range: 79–95), with a female/male sex ratio 
of 0.65. Patients had generally good status with 69% pre-
senting a PS 0 or 1. LDH levels were elevated in 64% 
of patients. Most patients (76%) presented with dissemi-
nated disease having an Ann Arbor stage III or IV, and 
37% had at least two extranodal sites. A total of 17.5% 
of the 114 evaluated patients had bone marrow involve-
ment, while disease in immune privilege organs (testis, 
ovaries, and breast) or the base of the skull was rare, 
occurring in less than 5% of patients.
Cumulative incidence, risk factors, and 
outcome of patients with CNS relapse
On- study data for CNS relapse and follow- up were not 
collected for one patient. After a median follow- up of 
28.7 months (range: 0.1–72.1), eight cases of CNS relapse 
(3.0%) were reported among the 269 patients analyzed 
(3.0%), five of whom who were receiving R- miniCHOP 
and three were receiving O- miniCHOP. Median time 
between inclusion and CNS relapse was 19.2 months 
(range: 3.2–32.6). The estimated 1- year and 2- year cumu-
lative incidence of CNS relapse was 1.16% and 1.80%, 
respectively (Fig. 1). As other relapse is considered as a 
competing event for CNS relapse, all the eight CNS relapse 
cases reported here are in first relapse.
Patients with CNS relapse had significantly worse sur-
vival than those without relapse, with a median OS of 
22.5 months (95% CI: 4.1–29.1) compared to median 
not reached (95% CI: 58.8 months to not reached), respec-
tively, and a hazard ratio of 3.77 (95% CI: 1.80–7.90, 
P = 0.004; Fig. 2).Two- year OS was 37.5% for patients 
with CNS relapse compared to 73.3% for patients without 
relapse (Fig. 2).
CNS- IPI classified 33 (12%) patients in the low- risk 
group, 165 (61%) in the intermediate- risk group, and 71 
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(26%) in the high- risk group. The proportion of patients 
with CNS disease did not differ significantly between 
patients with low- intermediate risk and patients with high 
risk according to CNS- IPI (3% vs. 2.8%, P = 1.00). No 
significant prognostic factor was identified for CNS relapse 
according to competing risk method.
Clinical profile of CNS relapse patients at 
lymphoma diagnosis
Taking into consideration, the relatively small number of 
patients with CNS relapse, clinical presentation at diagnosis 
of this subpopulation did not differ significantly from 
patients without CNS relapse for any of the parameters 
analyzed (Table 1). Median age was 83.5 years in the 
CNS relapse group. Five were male, six had disseminated 
disease, and high LDH levels were reported in five patients. 
Two patients had two or more extranodal sites, none of 
which involved immune privilege organs. One patient had 
cavum involvement. Six patients had an aaIPI of 2 or 3, 
while CNS- IPI was 1 (low risk) for one patient, 2–3 
(intermediate risk) for five patients, and 4 (high risk) for 
two patients. Six presented non- germinal centre B- cell- like 
(non- GCB) DLBCL, one had GCB DLBCL and data were 
Table 1. Clinical and biological characteristics of the global DLBCL population and according to CNS relapse
 
All DLBCL CNS relapse
P- value1N = 270
No 
N = 262
Yes 
N = 8
Study 0.74
LNH03- 7B/R- miniCHOP 150 (55.6%) 145 (55.3%) 5 (62.5%)
LNH09- 7B/O- miniCHOP 120 (44.4%) 117 (44.7%) 3 (37.5%)
Age (years) 0.66
Median (range) 83 (79–95) 83 (79–95) 83.5 (80–87)
Sex 0.27
Male 106 (39.3%) 101 (38.5%) 5 (62.5%)
Female 164 (60.7%) 161 (61.5%) 3 (37.5%)
Performance status (ECOG) 0.71
<2 185 (68.5%) 180 (68.7%) 5 (62.5%)
≥2 85 (31.5%) 82 (31.3%) 3 (37.5%)
LDH 1.00
≤Normal 98 (36.3%) 95 (36.3%) 3 (37.5%)
>Normal 172 (63.7%) 167 (63.7%) 5 (62.5%)
Ann Arbor stage 1.00
I–II 65 (24.1%) 63 (24.0%) 2 (25.0%)
III–IV 205 (75.9%) 199 (76.0%) 6 (75.0%)
IPI 1.00
0–2 82 (30.4%) 80 (30.5%) 2 (25.0%)
3–5 188 (69.6%) 182 (69.5%) 6 (75.0%)
Extranodal sites
Breast 13 (4.8%) 13 (5.0%) 0 (0.0%) 1.00
Gonads 9 (3.3%) 9 (3.4%) 0 (0.0%) 1.00
Kidney 10 (3.7%) 10 (3.8%) 0 (0.0%) 1.00
Adrenal 5 (1.9%) 5 (1.9%) 0 (0.0%) 1.00
Cavum 6 (2.2%) 5 (1.9%) 1 (12.5%) 0.22
Bone marrow (N = 114) 20 (17.5%) 20 (18.5%) 0 (0.0%) 0.67
Number of extranodal sites 0.71
<2 171 (63.3%) 165 (63.0%) 6 (75.0%)
≥2 99 (36.7%) 97 (37.0%) 2 (25.0%)
Age- adjusted IPI 0.71
0–1 103 (38.1%) 101 (38.5%) 2 (25.0%)
2–3 167 (61.9%) 161 (61.5%) 6 (75.0%)
CNS- IPI
Low risk (0–1 factors) 33 (12.3%) 32 (12.3%) 1 (12.5%) 1.00
Intermediate risk (2–3 factors) 165 (61.3%) 160 (61.3%) 5 (62.5%)
High risk (4–6 factors) 71 (26.4%) 69 (26.4%) 2 (25.0%)
LDH: Lactate dehydrogenase, aaIPI: age- adjusted International Prognostic Index.
1CNS versus no- CNS relapse populations were compared with Fisher’s exact or Wilcoxon Mann–Whitney (for age) tests. Missing data for 1 to 10 
patients for each parameter unless otherwise indicated.
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missing for one patient. By comparison, among the 133 
evaluable samples in the global population, 54.9% (73/133) 
were non- GCB DLBCL and 33.8% (45/133) were GCB. 
MYC expression was positive in between 30% and 50% 
of the cells in all four available samples, whereas among 
the 58 samples available for the global population, 53.5% 
(31/58) had ≥ 40% expression.
Description of the CNS relapse
Neurological symptoms at CNS relapse were either mild 
including loss of autonomy, asthenia, hearing impairment, 
urinary incontinence, or more prominent with delirium, 
aphasia, intracranial hypertension, or consciousness dis-
order (Table 2). Of the eight patients, all except one 
(with one missing data) presented at CNS relapse with 
Figure 1. Cumulative incidence of CNS relapse (N = 8), non- CNS relapse (N = 71), and death (N = 125) adjusted on IPI score in the global DLBCL 
population.
Figure 2. Kaplan–Meier analysis of overall survival in patients without relapse and in patients with CNS relapse and with non- CNS relapse, with 
number of subjects at risk and 95% confidence limits.
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ECOG PS ≥ 2. One patient had elevated LDH levels (miss-
ing data for two patients), all patients had exploratory 
imaging with a brain CT- scan, and three had a brain 
MRI, one of whom also had a lumbar puncture. All CNS 
relapses were parenchymal with no reports of meningeal 
disease, despite the very few number of completed lumbar 
puncture. Treatment of CNS relapse was proposed to five 
patients, entailed supportive care with corticosteroids in 
two patients, radiation therapy alone in one patient, radio- 
chemotherapy with rituximab/temodal (five cycles) in one 
patient, and chemotherapy alone including rituximab/
aracytine/vepeside (two cycles) in another. All eight patients 
progressed and died within 3 months.
Outcome comparison between patients with 
CNS relapse and patients with non- CNS 
relapse
Among the 270 patients, 71 (26.3%) patients presented 
non- CNS relapse. Median time between inclusion and 
non- CNS relapses was 8.1 months (range: 0.4–
29.2 months). Cumulative incidence of non- CNS relapse 
was 18.1% at 1 year and 23.4% at 2 years.
When comparing CNS and non- CNS patients, no dif-
ference was observed between baseline characteristics of 
patients with CNS relapse and patients with non- CNS 
relapse. Occurrence of CNS relapses and non- CNS relapses 
were observed in 50% and 74.6% of the patients within 
the first year after inclusion, and in 75% and 97.2% of 
patients within the two first years after inclusion, respec-
tively. Neither OS nor PFS was significantly different 
between the patients with CNS relapse compared to the 
patients with non- CNS relapse, with a median OS of 
22.5 months versus 15.1 months, respectively, (HR = 0.79, 
P = 0.53), and a median PFS of 12.1 months versus 
8.1 months, respectively, (HR = 0.49, P = 0.07). However, 
patients with CNS relapse had significantly worse survival 
from time of relapse than those with non- CNS relapse, 
with a median OS from relapse of 1.5 months (95% CI: 
0.4–3.5) compared to 6.6 months (95% CI: 4.6 –11.9), 
respectively, and a hazard ratio of 5.29 (95% CI: 2.36–11.88, 
P < 0.001; Fig. 3).
Discussion
Patients younger than 80 years are more likely to respond 
to and tolerate standard treatments than their older coun-
terparts [18, 19]. However with the number of older 
DLBCL patients steadily increasing, identifying the treat-
ment strategy optimally adapted to this typically fragile 
population and minimizing unnecessary treatment admin-
istration, is an important issue to address, particularly 
for specific cases such as CNS relapse. To the best of 
our knowledge, this is the first evaluation of CNS relapse 
in very elderly patients diagnosed with aggressive non- 
Hodgkin lymphoma. In this retrospective analysis of a 
cohort of 270 patients treated with miniCHOP combined 
with either rituximab or ofatumumab having a median 
age of 83 years (range: 79–95), CNS relapse was reported 
in 3% of the population after a median follow- up of 
nearly 2.5 years. This incidence in an elderly population 
falls within the range of published values, most of which 
include younger populations [5, 7–10, 21, 22]. CNS disease 
in elderly patients is particularly sticky to diagnose, given 
the frequently poor neurological symptoms and many 
confounding factors at this age of life, but the fine- tuned 
Figure 3. Kaplan–Meier analysis of specific overall survival after relapse for patients with CNS relapse and for patients with non- CNS relapse, with 
number of subjects at risk and 95% confidence limits.
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data collection in these prospective studies may have 
optimized CNS symptoms detection, and this value should 
reflect the real incidence of CNS relapse in elderly popu-
lation. It is of note that none of the 270 patients received 
CNS prophylaxis, which is driven by the absence of specific 
recommendations and the ubiquitous presence of comor-
bidities in this age group. Nonetheless, in this small 
population, the absence of prophylaxis did not appear to 
impact incidence of CNS relapse.
Among the eight patients with CNS relapse, five had 
elevated LDH levels, two had at least two extranodal sites, 
and six had aaIPI of 2 or 3—all of which have been 
identified as risk factors in younger populations [5, 7–10, 
21, 22]. Our analysis showed that incidence of these fac-
tors was not significantly different in patients with CNS 
relapse compared to those without. Savage et al. reported 
an increased likelihood of CNS relapse in MYC + DLBCL 
[23]. Although all four CNS relapse patients with MYC 
data showed MYC positivity, limited conclusions can be 
drawn with this small number of patients. Finally, CNS- 
IPI did not appear to be a predictor of CNS relapse in 
this elderly population, with equivalent incidences in 
patients categorized as low risk or intermediate risk com-
pared to those with high risk (3.0% vs. 2.8%), in contrast 
to the 0.8% for the low- risk, 3.9% for the intermediate- 
risk, and 12.0% for the high- risk groups reported in the 
validation cohort in the study by Schmitz et al. [15]. On 
one hand this leaves the relevance of this scale in older 
populations open to debate; given that the median age 
in the training cohort of their study was 58 years (18–80), 
while the validation cohort had a median age of 65 years 
(range: 16–94). On the other hand, it highlights the limi-
tation of the conclusions that can be drawn given the 
relatively small number of patients in our study. The 
neurologic symptoms reported in these older patients did 
not differ noticeably from those reported in younger 
patients.
Published results from the LNH03- 7B study support a 
survival advantage by associating low- dose chemotherapy 
(miniCHOP) with standard rituximab in selected very 
elderly DLBCL patients [4]. Preliminary results with ofa-
tumumab suggest a similar scenario for this alternative 
immunotherapy when associated with miniCHOP [20]. 
Nonetheless, these treatment regimens did not appear to 
have a dramatic impact on the effect of CNS relapse, 
with median OS dropping dramatically from median not 
reached (95% CI: 58.8 months to not reached) in patients 
with no relapse, with a 3.8- fold increased likelihood of 
death with CNS relapse and a median OS of only 
22.5 months (95% CI: 4.1–29.1). Given the small patient 
number in this study, it is difficult to interpret the pro-
portion of CNS relapse according to treatment type, with 
3.3% in the R- miniCHOP group versus 2.5% with 
O- miniCHOP. Similarly in the literature, this is open to 
debate with Feugier et al. reporting that the addition of 
rituximab to CHOP did not influence the risk of CNS 
occurrence [5], while Boehme et al. reported the inverse 
situation with CHOP- 14[7].
In our study, the median time between inclusion and 
CNS relapse of 19.2 months (range: 3.2–32.6) was remark-
ably long compared to several other studies, which report 
median durations ranging from 4.7 to 8.0 months [5, 
7–10, 21, 22]. One possible explanation is that this reflects 
the impact of the treatment combination R- miniCHOP 
improving OS in the overall very elderly population [4]. 
Nonetheless, this benefit does not appear to impact sur-
vival after CNS diagnosis, with death occurring after a 
median of 1.5 months (range: 0.4–4.1) which is shorter 
than for other younger populations, ranging from 2.4 to 
5.0 months [5, 7–10, 21, 22]. One interesting outcome 
of our study was the absence of difference in the OS 
when comparing the “CNS relapse” group and the “non- 
CNS relapse” group. Our analysis showed that any relapse, 
irrespective of its site, has a dramatic effect on OS.
An obvious limitation of this study is the relatively 
small sample size and the correspondingly small number 
of patients experiencing CNS relapse, reflecting the dif-
ficulty of recruiting patients of this age. It is also likely 
that the patient population recruited for a clinical trial 
does not accurately reflect the patient population seen in 
routine consultations, thereby introducing a bias which 
in turn offers better outcomes. In keeping with this, it 
is important to note that our population was in relatively 
good condition for this age group, with two- thirds of the 
population having a PS 0- 1 as well as no or only a single 
extranodal site of disease. These factors may also contribute 
to the above- mentioned long time between inclusion and 
CNS relapse and similar outcomes irrespective of site of 
relapse.
In conclusion, with the absence of prophylaxis not hav-
ing a dramatic impact on incidence, prophylaxis can be 
avoided in the very elderly given the potential for a nega-
tive impact of the associated toxicities. Accumulating data 
from more elderly patients is warranted to identify risk 
factors for CNS relapse in this population. In the future, 
new treatment approaches in the elderly including lena-
lidomide, currently tested in this population of patients 
by the LYSA (NCT02128061) or ibrutinib, may be efficient 
in elderly lymphoma patients experiencing CNS relapses.
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